Cargando…
Epidemiology of de novo Acute Myeloid Leukemia in Kuwait per the 2016 WHO Classification
OBJECTIVE: Acute myeloid leukemia (AML) is a hematological malignancy that arises from the clonal proliferation of immature myeloid cells. Although the number of AML cases has dramatically increased worldwide, information on its prevalence and incidence in Kuwait is lacking. This study reports the i...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275004/ https://www.ncbi.nlm.nih.gov/pubmed/35468599 http://dx.doi.org/10.1159/000524641 |
_version_ | 1784745403295465472 |
---|---|
author | Alshemmari, Salem H. Almazyad, Mazyad Ram, Mohan John, Liby Mariamma Alhuraiji, Ahmed |
author_facet | Alshemmari, Salem H. Almazyad, Mazyad Ram, Mohan John, Liby Mariamma Alhuraiji, Ahmed |
author_sort | Alshemmari, Salem H. |
collection | PubMed |
description | OBJECTIVE: Acute myeloid leukemia (AML) is a hematological malignancy that arises from the clonal proliferation of immature myeloid cells. Although the number of AML cases has dramatically increased worldwide, information on its prevalence and incidence in Kuwait is lacking. This study reports the incidence of AML and patient demographics in the country from 2014 to 2020, based on the 2016 WHO classification of AML. SUBJECTS AND METHODS: Data on patients with AML, including acute promyelocytic leukemia (APL), were collected from a clinical cohort with 281 cases analyzed in this study. RESULTS: The overall median age of the population was 47 years with a 1.1:1 male-to-female ratio. Over the study period, the incidence of AML demonstrated a general increasing trend, with the highest and lowest overall incidence occurring in 2018 and 2015, respectively. The frequency of APL in our cohort was 8.9%. Regarding the 2017 European LeukemiaNet (ELN) risk stratification of patients with AML, 37%, 46%, and 17% of patients had a favorable, intermediate, and adverse risk, respectively. A total of 57% of cases achieved complete remission post-induction, and the median overall survival was 37 months. CONCLUSION: Our study may help predict the future trends of AML in Kuwait to help improve clinical management and patient outcomes. |
format | Online Article Text |
id | pubmed-9275004 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-92750042022-08-16 Epidemiology of de novo Acute Myeloid Leukemia in Kuwait per the 2016 WHO Classification Alshemmari, Salem H. Almazyad, Mazyad Ram, Mohan John, Liby Mariamma Alhuraiji, Ahmed Med Princ Pract Original Paper OBJECTIVE: Acute myeloid leukemia (AML) is a hematological malignancy that arises from the clonal proliferation of immature myeloid cells. Although the number of AML cases has dramatically increased worldwide, information on its prevalence and incidence in Kuwait is lacking. This study reports the incidence of AML and patient demographics in the country from 2014 to 2020, based on the 2016 WHO classification of AML. SUBJECTS AND METHODS: Data on patients with AML, including acute promyelocytic leukemia (APL), were collected from a clinical cohort with 281 cases analyzed in this study. RESULTS: The overall median age of the population was 47 years with a 1.1:1 male-to-female ratio. Over the study period, the incidence of AML demonstrated a general increasing trend, with the highest and lowest overall incidence occurring in 2018 and 2015, respectively. The frequency of APL in our cohort was 8.9%. Regarding the 2017 European LeukemiaNet (ELN) risk stratification of patients with AML, 37%, 46%, and 17% of patients had a favorable, intermediate, and adverse risk, respectively. A total of 57% of cases achieved complete remission post-induction, and the median overall survival was 37 months. CONCLUSION: Our study may help predict the future trends of AML in Kuwait to help improve clinical management and patient outcomes. S. Karger AG 2022-04-25 /pmc/articles/PMC9275004/ /pubmed/35468599 http://dx.doi.org/10.1159/000524641 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. |
spellingShingle | Original Paper Alshemmari, Salem H. Almazyad, Mazyad Ram, Mohan John, Liby Mariamma Alhuraiji, Ahmed Epidemiology of de novo Acute Myeloid Leukemia in Kuwait per the 2016 WHO Classification |
title | Epidemiology of de novo Acute Myeloid Leukemia in Kuwait per the 2016 WHO Classification |
title_full | Epidemiology of de novo Acute Myeloid Leukemia in Kuwait per the 2016 WHO Classification |
title_fullStr | Epidemiology of de novo Acute Myeloid Leukemia in Kuwait per the 2016 WHO Classification |
title_full_unstemmed | Epidemiology of de novo Acute Myeloid Leukemia in Kuwait per the 2016 WHO Classification |
title_short | Epidemiology of de novo Acute Myeloid Leukemia in Kuwait per the 2016 WHO Classification |
title_sort | epidemiology of de novo acute myeloid leukemia in kuwait per the 2016 who classification |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275004/ https://www.ncbi.nlm.nih.gov/pubmed/35468599 http://dx.doi.org/10.1159/000524641 |
work_keys_str_mv | AT alshemmarisalemh epidemiologyofdenovoacutemyeloidleukemiainkuwaitperthe2016whoclassification AT almazyadmazyad epidemiologyofdenovoacutemyeloidleukemiainkuwaitperthe2016whoclassification AT rammohan epidemiologyofdenovoacutemyeloidleukemiainkuwaitperthe2016whoclassification AT johnlibymariamma epidemiologyofdenovoacutemyeloidleukemiainkuwaitperthe2016whoclassification AT alhuraijiahmed epidemiologyofdenovoacutemyeloidleukemiainkuwaitperthe2016whoclassification |